ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2017-017]

S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >=1cm Residual Invasive Cancer of Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >1 cm residual invasive breast cancer and/or positive lymph nodes (>ypN+) after chemotherapy. Patients are randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab).

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3071